免疫球蛋白市场规模、份额及成长分析（按适应症、剂型、给药途径、最终用户和地区）－2025-2032 年产业预测

2023 年免疫球蛋白市场规模价值 164 亿美元，预计将从 2024 年的 175.2 亿美元成长到 2032 年的 296.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.8%。

受免疫相关疾病盛行率上升以及诊断和治疗技术进步的推动，全球免疫球蛋白市场预计将经历显着增长。监管环境和不断增长的医疗保健支出进一步推动了这一扩张。技术创新和研发投入的增加正在提高免疫球蛋白治疗的品质和有效性。此外，新兴市场，特别是亚太和拉丁美洲，提供了巨大的成长机会。这些见解表明免疫球蛋白市场前景光明，敦促行业相关人员优先考虑技术创新、扩大生产能力并探索市场渗透策略，以满足对这些重要治疗方法日益增长的需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 专利分析

免疫球蛋白市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概览
• 原发性免疫力缺乏（PI）
• 继发性免疫力缺乏（SID）
• 慢性脱髓鞘多发性神经炎(CIDP)
• 格林-巴利综合症
• 免疫性血小板减少性紫斑症（ITP）
• 多灶性运动神经病变(MMN)
• 其他的

免疫球蛋白市场规模（以剂型划分）及复合年增长率（2025-2032）

• 市场概览
• 液体
• 冷冻干燥

免疫球蛋白市场规模（按给药途径和复合年增长率） (2025-2032)

• 市场概览
• 静脉
• 皮下

免疫球蛋白市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 诊所
• 居家护理
• 其他的

免疫球蛋白市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Grifols（Spain）
• CSL Limited（Australia）
• Octapharma（Switzerland）
• Kedrion Biopharma（Italy）
• Biotest AG（Germany）
• LFB Group（France）
• Shanghai RAAS Blood Products（China）
• China Biologic Products Holdings（China）
• Baxter International Inc.（USA）
• Takeda Pharmaceutical Company（Japan）
• Sanquin（Netherlands）
• Bio Products Laboratory（UK）
• Emergent BioSolutions（USA）
• ADMA Biologics（USA）
• Kamada Ltd.（Israel）
• Green Cross Corporation（South Korea）
• SK Plasma（South Korea）
• Hualan Biological Engineering Inc.（China）
• Beijing Tiantan Biological Products（China）
• Shire Plc（UK）

结论和建议

Immunoglobulin Market size was valued at USD 16.4 billion in 2023 and is poised to grow from USD 17.52 billion in 2024 to USD 29.65 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global Immunoglobulin market is poised for considerable growth, fueled by the rising incidence of immunological disorders and advancements in diagnostic and therapeutic techniques. A supportive regulatory landscape and increasing healthcare expenditures further bolster this expansion. Innovations and heightened investment in research and development are enhancing the quality and effectiveness of Immunoglobulin therapies. Additionally, emerging markets, notably in the Asia-Pacific and Latin America regions, offer substantial opportunities for growth. These insights suggest a promising outlook for the Immunoglobulin market, encouraging industry stakeholders to prioritize innovation, scale up capacities, and explore market penetration strategies to satisfy the growing demand for these vital therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunoglobulin Market Segments Analysis

Global Immunoglobulin Market is segmented by Indication, Form, Route of Administration, End-User and region. Based on Indication, the market is segmented into Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain Barre Syndrome, Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN) and Others. Based on Form, the market is segmented into Liquid and Lyophilized. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, Intramuscular. Based on End-User, the market is segmented into Hospitals, Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Immunoglobulin Market

A significant driver of the global Immunoglobulin market is the rising incidence of immunological disorders. Immunoglobulins are essential for treating a variety of conditions, including primary immunodeficiencies, autoimmune diseases, and infectious diseases. The growing prevalence of these disorders, enhanced by better diagnostic methods and increased awareness, is driving the demand for Immunoglobulin therapies. Contributing factors include genetic susceptibility, environmental influences, and lifestyle shifts that lead to a higher occurrence of immunological issues worldwide. Moreover, improvements in healthcare infrastructure, greater access to medical services, and increasing healthcare spending are also pivotal in propelling the market's expansion.

Restraints in the Immunoglobulin Market

A major constraint faced by the global Immunoglobulin market is the steep cost associated with Immunoglobulin therapies. The intricate processes required for the production, purification, and storage of these therapies contribute to elevated manufacturing expenses, which in turn lead to higher prices for patients and healthcare systems. This financial barrier is particularly pronounced in developing nations where healthcare resources are limited and affordability is a critical concern. Additionally, reimbursement challenges and restricted insurance coverage further exacerbate the financial strain on individuals seeking these therapies. Consequently, it is vital to explore strategies aimed at minimizing production costs, fostering market competition, and enhancing the availability of affordable Immunoglobulin treatments to improve patient access and care.

Market Trends of the Immunoglobulin Market

The global Immunoglobulin market is witnessing a prominent trend characterized by a surge in the adoption of intravenous immunoglobulin (IVIG) therapy. This therapy, crucial for patients with immunodeficiency disorders, autoimmune diseases, and specific neurological conditions, has gained traction due to its proven efficacy and the heightened awareness of its therapeutic benefits among healthcare professionals and patients alike. Innovations in production technologies, enhanced product safety standards, and the broadening scope of IVIG indications are fueling this adoption. Concurrently, the rising incidence of immunological disorders and an aging population are further propelling the demand for Immunoglobulin products, solidifying IVIG therapy's pivotal role in modern medicine.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Patent Analysis

Global Immunoglobulin Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Primary Immunodeficiency (PI)
• Secondary Immunodeficiency (SID)
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Guillain Barre Syndrome
• Immune Thrombocytopenic Purpura (ITP)
• Multifocal Motor Neuropathy (MMN)
• Others

Global Immunoglobulin Market Size by Form & CAGR (2025-2032)

• Market Overview
• Liquid
• Lyophilized

Global Immunoglobulin Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Subcutaneous

Global Immunoglobulin Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Homecare
• Others

Global Immunoglobulin Market Size & CAGR (2025-2032)

• North America (Indication, Form, Route of Administration, End-User)
  • US
  • Canada
• Europe (Indication, Form, Route of Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Form, Route of Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Form, Route of Administration, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Form, Route of Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Grifols (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK Plasma (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Tiantan Biological Products (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations